Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Expands Into Asia With Korean Hospital Deal

CHICAGO (GenomeWeb) – Syapse, a maker of software to support precision oncology care, has entered the Asian market through a partnership with Seoul National University Hospital. A parallel deal with cloud IT company Megazone will allow the company to reach other potential customers in South Korea, Japan, and Vietnam.

Seoul National University Cancer Hospital will install the Syapse data-aggregation platform in its 28 centers across Korea, while Megazone, a major Amazon Web Services consulting partner in Asia, will provide IT support, the three entities said today. SNUH said oncologists should be able to make better treatment decisions with the help of Syapse's molecular analysis technology.

The South Korean health system is Syapse's first customer outside the US, the vendor said.

"SNUH has long been on the cutting edge in both cancer care and technology, and I’m thrilled to be partnering with them to help bring precision medicine to patients in South Korea,"  Syapse CEO Ken Tarkoff said in a statement.

"Through our precision medicine platform, we hope Seoul National University Hospital will provide a new standard for the evidence-based precision treatment of cancer," added SNUH Chief Information Officer Kyung Hwan Kim, a cardiothoracic surgeon.

San Francisco-based Syapse raised $30 million in new venture capital last fall to support such expansions.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more